NKTR
NASDAQ · Pharmaceuticals
Nektar Therapeutics
$60.98
+0.06 (+0.10%)
Financial Highlights (FY 2026)
Revenue
110.61M
Net Income
-328,582,638
Gross Margin
100.0%
Profit Margin
-297.1%
Rev Growth
-15.7%
D/E Ratio
0.70
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 33.1% | 33.1% |
| Operating Margin | -253.7% | -228.3% | 30.6% | 35.1% |
| Profit Margin | -297.1% | -282.2% | 23.0% | 25.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 110.61M | 131.16M | 246.52M | 245.87M |
| Gross Profit | 110.61M | 131.16M | 81.64M | 81.42M |
| Operating Income | -280,570,025 | -299,434,391 | 75.50M | 86.21M |
| Net Income | -328,582,638 | -350,675,173 | 56.66M | 62.08M |
| Gross Margin | 100.0% | 100.0% | 33.1% | 33.1% |
| Operating Margin | -253.7% | -228.3% | 30.6% | 35.1% |
| Profit Margin | -297.1% | -282.2% | 23.0% | 25.3% |
| Rev Growth | -15.7% | -15.7% | +15.2% | +17.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 425.28M | 425.28M | 257.51M | 280.38M |
| Total Equity | 604.86M | 604.86M | 292.45M | 319.03M |
| D/E Ratio | 0.70 | 0.70 | 0.88 | 0.88 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -278,515,123 | -313,754,733 | 106.98M | 112.84M |
| Free Cash Flow | — | — | 45.61M | 47.98M |